Back to News & Events

Celmatix to Partner with 23andMe

Celmatix has announced a collaboration with 23andMe, the leading personal genetics company, with the goal of improving infertility outcomes. This collaboration will accelerate the launch of Celmatix’s tests, which will aim to provide physicians with a comprehensive genetic lens on infertility. This will also enable the development of early screening tests which will help OBGYNs identify women who are at risk for premature decline of their ovarian function, which has both infertility and broader health implications. Read the announcement here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3083 [post_author] => 3 [post_date] => 2018-11-16 14:26:57 [post_date_gmt] => 2018-11-16 14:26:57 [post_content] => Update courtesy of BBC Entrepreneurial Training and Consulting NIH is strongly encouraging small businesses to contact the appropriate Institute or Center early in their application planning to ensure their technology is a priority for the Institute/Center. An updated SBIR/STTR Application Guide with additional instructions for SBIR Direct Phase II application preparation and submission will be posted by November 26, 2018. The following sections of each FOA are changed: Part 2, Section I. Funding Opportunity Description The following has been added at the end of the section for each FOA: PA-18-573 The following Components will not accept an SBIR Direct-to-Phase II submission: - National Institute of Nursing Research (NINR) - National Center for Complementary and Integrative Health (NCCIH) PA-18-574 The following Components will not accept an SBIR Direct-to-Phase II submission: - National Institute of Environmental Health Sciences (NIEHS ) - National Institute of Nursing Research (NINR) - National Center for Complementary and Integrative Health (NCCIH) - Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs (ORIP) - Centers for Disease Control and Prevention (CDC) (All Components of CDC) - U.S. Food and Drug Administration (FDA) (All Components of FDA) Part 2, Section II. Award Information for both PA-18-573 and PA-18-574. Application types now allowed are: - New (Phase I, Fast-Track) - New (Direct Phase II) - Renewal (Phase II) - Resubmission (all phases) - Phase IIB Competing Renewal (Phase IIB) - Revision The OER Glossary and the SF424 (R&R) SBIR/STTR Application Guide provide details on these application types. [post_title] => Important SBIR/STTR Information Update from NIH [post_excerpt] => An updated SBIR/STTR Application Guide with additional instructions for SBIR Direct Phase II application preparation and submission will be posted by November 26, 2018. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => important-sbirsttr-information-update-from-nih [to_ping] => [pinged] => [post_modified] => 2018-11-16 14:26:57 [post_modified_gmt] => 2018-11-16 14:26:57 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=3083 [menu_order] => 110 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2696 [post_author] => 1 [post_date] => 2017-05-05 18:16:15 [post_date_gmt] => 2017-05-05 18:16:15 [post_content] => CFB Director of Operations, Diane Fabel, has been inducted into the Stony Brook University Chapter of the National Academy of Inventors (NAI-SBU) as an honorary member. At the chapter’s Annual Meeting on May 1, 2017, 16 new members and 2 honorary members were inducted into the Academy. Ms. Fabel and her fellow inductees join 30 stony brook faculty members, including CFB Director Clinton Rubin, who were inducted as inaugural members to the SBU-NAI in 2016.

Read more on the chapter and this year’s inductees here.

[post_title] => CFB Operations Director Inducted into SBU Chapter of the National Academy of Inventors [post_excerpt] => May 1, 2017, the CFB's Director of Operations was inducted into the Stony Brook University Chapter of the National Academy of Inventors (NAI-SBU) as an honorary members. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => cfb-operations-director-inducted-into-sbu-chapter-of-the-national-academy-of-inventors [to_ping] => [pinged] => [post_modified] => 2017-05-19 18:29:23 [post_modified_gmt] => 2017-05-19 18:29:23 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2696 [menu_order] => 146 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2878 [post_author] => 1 [post_date] => 2017-11-21 14:36:09 [post_date_gmt] => 2017-11-21 14:36:09 [post_content] => The proposal submission deadline for the SUNY Technology Accelerator Fund Class of 2018 is February 16, 2018. Faculty, staff, and students from all disciplines and campuses are encouraged to submit proposals for the SUNY Technology Accelerator Fund Class of 2018 funding. The deadline for submitting proposals is February 16, 2018. See TAF Class of 2018 Application and Administrative Guidelines. The SUNY Technology Accelerator Fund (“TAF”) provides funding to support the advancement of SUNY innovations from the lab to the marketplace. Since its launch in 2011, the TAF has successfully advanced the commercial readiness of a number of SUNY-developed innovations. In most cases, SUNY innovations developed through sponsored research lack critical proof-of-concept data that is needed to attract investment by potential licensees or investors. TAF support targets the critical milestones needed to demonstrate that an innovation is worthy of external investment. TAF’s strategic objective is to facilitate the commercialization of SUNY-developed innovations for the public benefit in an expeditious and effective manner. The aim is to identify opportunities where small investments will provide significant impacts on making SUNY innovations available to the public. Different from fundamental research, TAF investments support proof-of-concept and technology development projects to validate the commercial feasibility of SUNY technology. The goal is to facilitate the translation of SUNY technology into marketable products and/or services by enhancing strategic academic-industry partnerships and building new entrepreneurial Please be advised that all proposals require the review and participation of your campus administration prior to submission. To be certain that you adhere to any local proposal submission deadlines, we urge you to immediately contact your technology transfer office and/or office of sponsored programs if you are interested in applying for TAF Class of 2018 funding. Questions? Please send any questions to TAF@rfsuny.org. All questions and answers will be posted to www.rfsuny.org/taf. [post_title] => Funding Opportunity: SUNY Technology Accelerator Fund Accepting Proposals [post_excerpt] => Proposal Deadline for the SUNY Technology Accelerator Fund Class of 2018 is February 16, 2018! SUNY Technology Accelerator Fund (“TAF”) provides funding to support the advancement of SUNY innovations from the lab to the marketplace. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => funding-opportunity-suny-technology-accelerator-fund-accepting-proposals-2 [to_ping] => [pinged] => [post_modified] => 2018-01-23 14:38:56 [post_modified_gmt] => 2018-01-23 14:38:56 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2878 [menu_order] => 135 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 256 [max_num_pages] => 86 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

Important SBIR/STTR Information Update from NIH

More Information

CFB Operations Director Inducted into SBU Chapter of the National Academy of Inventors

More Information

Funding Opportunity: SUNY Technology Accelerator Fund Accepting Proposals

More Information